Evidence map›Paper›PMID 39284942›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2024

Comparison between clinical and cytological findings in chronic rhinosinusitis with nasal polyps treated with Dupilumab.

Andrea Ciofalo, Antonella Loperfido, Silvia Baroncelli, Simonetta Masieri, Gianluca Bellocchi, Riccardo Caramia, Francesca Cascone, Luca Filaferro, Federica Lo Re, Carlo Cavaliere

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Remission in chronic rhinosinusitis with nasal polyps treated with biologics: a real-life experience.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Observational
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrea CiofaloDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0003-1468-459X
Antonella LoperfidoOtolaryngology Unit, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, 00152, Italy. aloperfido@scamilloforlanini.rm.it.ORCID http://orcid.org/0000-0002-7174-8126
Silvia BaroncelliNational Center for Global Health, Istituto Superiore di Sanità, Rome, 00161, Italy.ORCID http://orcid.org/0000-0002-2050-9037
Simonetta MasieriDepartment of Oral and Maxillofacial Sciences, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0003-0423-9505
Gianluca BellocchiOtolaryngology Unit, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, 00152, Italy.ORCID http://orcid.org/0000-0001-5341-3309
Riccardo CaramiaDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.
Francesca CasconeDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0002-6900-104X
Luca FilaferroDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0003-4002-0498
Federica Lo ReDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0003-2579-1219
Carlo CavaliereDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0002-0378-8935

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBiologics represent a new therapeutic strategy for severe and recurrent chronic rhinosinusitis with nasal polyps (CRSwNP). Usually, their actual therapeutic effectiveness is assessed by reduction in nasal polyps and/or improvement in nasal symptoms and quality of life. However, these measures do not consider nasal immunophlogosis, which can be evaluated through nasal cytology. The purpose of this study was to assess not only the clinical impact but also the cellular changes in the nasal inflammatory infiltrate observed through nasal cytology of CRSwNP patients treated with Dupilumab for 24 months.

methodsFifty-five CRSwNP patients treated with Dupilumab were collected. Patients were evaluated before starting treatment and at one, three, six, nine months, one year, one and a half years, and two years after the first drug administration. During follow-up visits patients underwent endoscopic evaluation, nasal symptoms and quality of life assessment, complete blood count and nasal cytology.

resultsDuring follow-up, significant improvement was found in Nasal Polyps Score (NPS), nasal patency, olfaction, Sino-Nasal Outcome Test (SNOT-22) score, and Visual Analogue Scale (VAS). Regarding nasal cytology, a reduction in eosinophils and mast cells in the cellular infiltrate was observed over the two-year follow-up period compared to baseline.

conclusionDupilumab has demonstrated broad efficacy in the management of CRSwNP from both clinical and cytological findings. Further studies are needed to confirm our findings and evaluate the biologics' impact on nasal mucosal inflammatory cells by nasal cytology with the aim of better identifying each patient's endotype and predicting the response to biologics.

Indexed as

Antibodies, Monoclonal, HumanizedNasal PolypsQuality of LifeRhinitisSinusitisAdultAgedChronic DiseaseEosinophilsFemaleHumansMaleMiddle AgedNasal MucosaRhinosinusitisTreatment OutcomeAntibodies, Monoclonal, HumanizeddupilumabBiologicsChronic rhinosinusitis with nasal polypsDupilumabEosinophilsNasal cytologyType 2 inflammation

Identifiers

PMID39284942

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.